Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon

Leukemia Research Reports(2020)10.1016/j.lrr.2020.100211Source: DataRank Database

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon is a research paper published in Leukemia Research Reports (2020). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 0.57)OA: goldTopics (27)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Zoe McKinnell,Jae H. Park ORCID,Eytan M. Stein ORCID,Sheng F. Cai ORCID,Justin Taylor ORCID

Live enrichment

PubMed:32637309 PMC:PMC7327424 OpenAlex:https://openalex.org/W3034464376

National Cancer Institute

Grant: 1K08CA230319-01

Defining the Biological and Mechanistic Implications of XPO1 Mutations in Hematologic Malignancies

Leukemia and Lymphoma Society

Grant: 545317

NCI NIH HHS

Grant: P30 CA008748

Leukemia & Lymphoma Society

Grant: 545317

Mark Foundation for Cancer Research

NIH

Rally Foundation for Childhood Cancer Research

Robert Wood Johnson Foundation

Truth 365

American Association for Cancer Research

NCI

American Society of Hematology

Conquer Cancer Foundation

FWCI

0.57

Citation Percentile

0.7%

Citation Trend

2020

2021

2022

2023

2024

2025

goldLicense: cc-by-nc-nd

journalhttps://www.sciencedirect.com/science/article/pii/S2213048920300170/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2213048920300170/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2213048920300170?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2213048920300170?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.lrr.2020.100211

Fields of Study

Chronic Myeloid Leukemia TreatmentsEosinophilic Disorders and SyndromesMyeloproliferative Neoplasms: Diagnosis and Treatment03 medical and health sciences0302 clinical medicine

Keywords

MedicineTyrosine-kinase inhibitorTyrosine kinaseChronic myelogenous leukemiaProteinuriaAcute kidney injuryNephropathyImatinibInternal medicinePharmacologyOncologyLeukemiaKidneyMyeloid leukemiaChronic myeloid leukemiaNilotinibDasatinibBcr-ablPonatinibNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being